Navigation Links
Adoption of Consumer-Driven Health Plans Accelerated by Recession
Date:4/13/2009

NASHVILLE, Tenn., April 13 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that more employers are opting for consumer-driven health plans (CDHP) as they look for ways to reduce costs. The individual CDHP market is also growing as the unemployed look for affordable health insurance options. According to recent Health Plan Analysis reports, employers will continue to utilize account-based and high-deductible options in light of strained budgets and anticipated increases in premiums.

"We're seeing increases in CDHP enrollment across the board, both in places like Minnesota where employers were early-adopters of high-deductible plans and now in areas like North Carolina that have been hit hard by the economic downturn," said Paula Wade, assistant director, Health Plan Analysis. "What remains to be seen is how the federal COBRA subsidy will reduce demand for individual consumer-driven plans, as more workers elect to continue group benefits through COBRA instead of choosing an individual CDHP."

The federal subsidy for COBRA insurance is part of the federal stimulus package and includes a 65 percent subsidy on the cost of COBRA premiums for up to nine months.

Drug Coverage and CDHPs

According to the recent North & South Carolina Health Plan Analysis, wellness and pharmaceutical benefits will be an important element of CDHPs' success.

"Many CDHPs cover only generic medications and lower-cost options, if they carry a pharmacy benefit at all," said Wade. "As a result, the pharmaceutical industry has a vested interest in consumers selecting COBRA coverage over an individual CDHP, because the group plan is more likely to have more substantial drug coverage."

Why Pharmaceutical Companies Need Health Plan Analysis

Health Plan Analysis identifies key health plan trends, allowing pharmaceutical companies to create comprehensive strategic plans and sales strategies at state and local levels. Updated quarterly, Health Plan Analysis provides a detailed look at plan design and financials, as well as information about mergers, legislation and other influencers driving healthcare in a particular region.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Lisa Osgood               Elizabeth Marshall
    HealthLeaders-InterStudy  Decision Resources, Inc.
    781-296-2606              781-296-2563
    losgood@hl-isy.com        emarshall@dresources.com

'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. iMedica Launches Transition™, a New, Streamlined EHR That Breaks Down the Barriers to Physician Adoption and Use
2. Parents sexuality influences adoption choices
3. In Malawi, Adoption is Not Enough
4. Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3
5. Massachusetts Studies Reveal Importance of Incentives in Healthcare Technology Adoption
6. Barriers to adoption of electronic personal health records outlined
7. Patient Safety Technologies, Inc. Announces the Adoption of the Safety-Sponge(TM) System by the First Hospital in the State of Indiana
8. OSMAs EMR Standards of Excellence Program Eases EMR Adoption Process
9. Allscripts Survey of Healthcare Professionals Demonstrates Potential Impact of Economic Stimulus Plan on Electronic Health Record Adoption
10. Xmark Sends Letters to Icagens Board of Directors: Questions Companys Leadership as Well as Motives Behind Adoption of Poison Pill
11. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology: